Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Zhixian Yu
Observed name:
Z. Yu
Institution:
First Affiliated Hospital of Wenzhou Medical University
Observed institution:
First Affiliated Hospital of Wenzhou Medical University
ORCID:
0000-0002-1226-7891
Observed ORCID:
0000-0002-1226-7891
OpenAlex ID:
A5055372532
Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer
2025
·
Xinan Sheng
, Gongqian Zeng
, et al.
·
New England Journal of Medicine
·
121
Efficacy and Safety of BL-B01D1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma: A Phase II Clinical Trial
2025
·
Xiaojie Bian
, Tiejun Yang
, et al.
·
Journal of Clinical Oncology
·
14
A dynamic online nomogram predicting prostate cancer short-term prognosis based on 18F-PSMA-1007 PET/CT of periprostatic adipose tissue: a multicenter study
2024
·
Shuying Bian
, Weifeng Hong
, et al.
·
Abdominal Radiology
·
9
Risk Evaluation of Bone Metastases and a Simple Tool for Detecting Bone Metastases in Prostate Cancer: A Population‐Based Study
2023
·
Shi Li
, Caixia Chen
, et al.
·
Computational and Mathematical Methods in Medicine
·
6
PDF
Distinct Clinicopathological Features of HER2 ‐Negative, HER2 ‐Low, and HER2 ‐Overexpressing Urothelial Carcinoma in a Large Chinese Cohort
2025
·
Shanshan Wang
, Dingwei Ye
, et al.
·
Cancer Medicine
·
2
PDF
Clinical Outcomes and Safety Profile of Neoadjuvant PD-1 Inhibitors Combined With VEGFR-TKI Versus VEGFR-TKI in Nonmetastatic Renal Cell Carcinoma
2025
·
Cheoklong Ng
, Cheng Peng
, et al.
·
Clinical Genitourinary Cancer
·
2
Combined fibrinogen concentration and neutrophil-to-lymphocyte ratio, an integrative model of the inflammatory response and coagulation cascades, for predicting prognosis in patients with upper tract urothelial carcinoma
2024
·
Yangqing Zheng
, Chen Chen
, et al.
·
Biomolecules and Biomedicine
·
2
Phase 2 study of YL201, an anti-B7H3 antibody–drug conjugate (ADC), in heavily pretreated metastatic castration-resistant prostate cancer (mCRPC).
2026
·
Dingwei Ye
, Zhisong He
, et al.
·
Journal of Clinical Oncology
·
1
Neoadjuvant treatment with disitamab vedotin plus perioperative toripalimab in patients with HER2-expressing muscle-invasive bladder cancer (MIBC) in the phase II RC48-C017 trial: Updated results.
2026
·
Xinan Sheng
, Cuijian Zhang
, et al.
·
Journal of Clinical Oncology
·
1
Identification of LIMK1 as a biomarker in clear cell renal cell carcinoma: from data mining to validation
2025
·
Yifei Li
, Congcong Fan
, et al.
·
Journal of Cancer Research and Clinical Oncology
·
1
Titration as an effective strategy to reduce apalutamide induced skin rash: A multi-institutional real-world experience.
2023
·
Zhixian Yu
, Kaiyuan Yu
, et al.
·
Journal of Clinical Oncology
·
1
PDF
Phase 1/2 study of an anti-PD-L1/IL-15 variant fusion protein (SIM0237) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC).
2026
·
Dingwei Ye
, Hua Xu
, et al.
·
Journal of Clinical Oncology
Sacituzumab tirumotecan (Sac-TMT) plus pembrolizumab (Pembro) in participants (Pts) with advanced urothelial carcinoma (UC): Results from phase 2 2870-002/SKB264-II-06 study.
2026
·
Xiaojie Bian
, Fang-Jian Zhou
, et al.
·
Journal of Clinical Oncology
PDF
Phase 1 safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of pasritamig in Asian population with metastatic castration-resistant prostate cancer (mCRPC).
2026
·
Junyong Dai
, Nan Liu
, et al.
·
Journal of Clinical Oncology
PDF
540O Fruquintinib monotherapy as second-line (2L) treatment in locally advanced or metastatic renal cell carcinoma (RCC): Results from phase II part of FRUSICA-2
2025
·
D. Ye
, Z. He
, et al.
·
Annals of Oncology
Show more works
View as search
Works count:
15
Citation count:
160
H-index:
4
I10-index:
2
Year
Topic
Type